You just read:

Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström's Macroglobulinemia Met Primary Endpoint

News provided by

Janssen Research & Development, LLC

Dec 05, 2017, 07:05 ET